Published 2005 | Version v1
Journal article

Development of 62Zn bleomycin as a possible PET tracer

  • 1. M. Kamali-Dehghan Cyclotron and Nuclear Medicine Department, Nuclear Research Center for Agriculture and Medicine (NRCAM), Atomic Energy Organization of Iran (AEOI), Karaj (Iran, Islamic Republic of)
  • 2. Research and Science Unit, Faculty of Engineering, Islamic Azad University of Iran, Tehran (Iran, Islamic Republic of)
  • 3. Medical Physics Department, Shahid Beheshti University of Medical Sciences, Tehran (Iran, Islamic Republic of)

Description

Bleomycin (BLM), labeled with radioisotopes, is widely used in therapy and diagnosis. In this study, BLM was labeled with 62Zn for oncologic PET studies. The complex was obtained at pH = 2 in saline at 90oC in 25 min. Radio-TLC showed an overall radiochemical yield of 95-97% (radiochemical purity > 97%). Stability of complex was checked in vitro in mice and human plasma/urine. Preliminary in vivo studies were performed to determine complex stability and distribution of 62Zn BLM in normal and fibrosarcoma-bearing mice. 62Zn BLM accumulated significantly in induced fibrosarcoma tumors in mice according to biodistribution/imaging studies. 62Zn BLM can be used in PET oncology studies due to its suitable physicochemical properties as a diagnostic complex in vitro and in vivo. Further studies should be performed for evaluation of the complex behavior in larger mammals. (author)

Additional details

Publishing Information

Journal Title
Nukleonika
Journal Volume
50
Journal Issue
4
Series
19 refs., 2 tabs., 7 figs.
Journal Page Range
p. 143-148
ISSN
0029-5922